Emerging therapies for pulmonary arterial hypertension

Bibliography

• LANE KB, MACHADO RD, PAUCIULO MW et al.: Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. (2000) 26:81-84.
   PubMed Web of Science ®Google Scholar
• DENG Z, MORSE JH, SLAGER SL et al.: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. (2000) 67:737-744.
   PubMed Web of Science ®Google Scholar
• TREMBATH RC, THOMSON JR, MACHADO RD et al.: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med. (2001) 345:325-334.
   PubMed Web of Science ®Google Scholar
• COGAN JD, PAUCIULO MW, BATCHMAN AP et al.: High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2006) 174:590-598.
   PubMed Web of Science ®Google Scholar
• DU L, SULLIVAN CC, CHU D et al.: Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med. (2003) 348:500-509.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, GOTO N, KOJIMA Y et al.: Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. (2006) 290:L450-L458.
   PubMed Web of Science ®Google Scholar
• CALDWELL RL, GADIPATTI R, LANE KB, SHEPHERD VL: HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J. Leukoc. Biol. (2006) 79:192-201.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, SITBON O, CHAOUAT A et al.: Pulmonary arterial hypertension in france: results from a national registry. Am. J. Respir. Crit. Care Med. (2006) 173:1023-1030.
   PubMed Web of Science ®Google Scholar
• MACHADO RD, ALDRED MA, JAMES V et al.: Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat. (2006) 27:121-132.
   PubMed Web of Science ®Google Scholar
• BADESCH DB, ABMAN SH, AHEARN GS et al.: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126:35S-62S.
   PubMed Web of Science ®Google Scholar
• GALIE N, TORBICKI A, BARST R et al.: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. (2004) 25:2243-2278.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351:1425-1436.
   PubMed Web of Science ®Google Scholar
• CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358:1119-1123.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346:896-903.
   PubMed Web of Science ®Google Scholar
• GALIE N, MANES A, BRANZI A: The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. (2004) 61:227-237.
   PubMed Web of Science ®Google Scholar
• LEE SH, RUBIN LJ: Current treatment strategies for pulmonary arterial hypertension. J. Intern. Med. (2005) 258:199-215.
   PubMed Web of Science ®Google Scholar
• MOTTE S, MCENTEE K, NAEIJE R: Endothelin receptor antagonists. Pharmacol. Ther. (2006) 110:386-414.
   PubMed Web of Science ®Google Scholar
• SEBKHI A, STRANGE JW, PHILLIPS SC, WHARTON J, WILKINS MR: Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 107:3230-3235.
   PubMed Web of Science ®Google Scholar
• WHARTON J, STRANGE JW, MOLLER GM et al.: Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. (2005) 172:105-113.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, OSTERLOH IH, GRIMMINGER F: Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. (2006) 5:689-702.
   PubMed Web of Science ®Google Scholar
• GALIE N, GHOFRANI HA, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353:2148-2157.
   PubMed Web of Science ®Google Scholar
• WILKINS MR, PAUL GA, STRANGE JW et al.: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. (2005) 171:1292-1297.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. (2004) 44:1488-1496.
   PubMed Web of Science ®Google Scholar
• BADESCH DB, MCLAUGHLIN VV, DELCROIX M et al.: Prostanoid therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43:56S-61S.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI H, SIMONNEAU G, GALIE N et al.: Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. (2002) 347:322-329.
   PubMed Web of Science ®Google Scholar
• SIMONNEAU G, BARST RJ, GALIE N et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (2002) 165:800-804.
   PubMed Web of Science ®Google Scholar
• VOSWINCKEL R, ENKE B, REICHENBERGER F et al.: Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J. Am. Coll. Cardiol. (2006) 48:1672-1681.
   PubMed Web of Science ®Google Scholar
• CHANNICK RN, OLSCHEWSKI H, SEEGER W, STAUB T, VOSWINCKEL R, RUBIN LJ: Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2006) 48:1433-1437.
   PubMed Web of Science ®Google Scholar
• VOSWINCKEL R, ENKE B, REICHENBERGER F et al.: Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J. Am. Coll. Cardiol. (2006) 48:1672-1681.
   PubMed Web of Science ®Google Scholar
• KUWANO K, HASHINO A, ASAKI T et al.: NS-304, an orally available and long-acting prostacyclin receptor agonist, as an improved drug for pulmonary arterial hypertension. Circulation (2005) 112:U258.
   Google Scholar
• KATAOKA M, NAGAYA N, SATOH T et al.: A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 172:1575-1580.
   PubMed Web of Science ®Google Scholar
• ADATIA I, BARROW SE, STRATTON PD, MIALL-ALLEN VM, RITTER JM, HAWORTH SG: Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation (1993) 88:2117-2122.
   PubMed Web of Science ®Google Scholar
• CHRISTMAN BW, MCPHERSON CD, NEWMAN JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. (1992) 327:70-75.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, ROSE F, SCHERMULY RT et al.: Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 42:158-164.
   PubMed Web of Science ®Google Scholar
• GROWCOTT EJ, SPINK KG, REN X, AFZAL S, BANNER KH, WHARTON J: Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir. Res. (2006) 7:9.
   PubMed Web of Science ®Google Scholar
• SCHERMULY RT, INHOLTE C, GHOFRANI HA et al.: Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir. Res. (2005) 6:76.
   PubMedGoogle Scholar
• ALI FY, EGAN K, FITZGERALD GA et al.: Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts. Am. J. Respir. Cell Mol. Biol. (2006) 34:242-246.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, UEMATSU M, OYA H et al.: Short-term oral administration of l-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2001) 163:887-891.
   PubMed Web of Science ®Google Scholar
• MANES A, BAUTISTA E, OLCHEWSKI H, TORBICKI A, GALIE N: l-Arginine supplementation in pulmonary arterial hypertension. Eur. Heart J. (2004) 25:21.
   Google Scholar
• KHOO JP, ZHAO L, ALP NJ et al.: Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 111:2126-2133.
   PubMed Web of Science ®Google Scholar
• NANDI M, LEIPER J, ARRIGONI F, HISLOP A, VALLANCE P, HAWORTH S: Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation. Pediatr. Res. (2006) 59:767-772.
   PubMed Web of Science ®Google Scholar
• DERUELLE P, GROVER TR, ABMAN SH: Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 289:L798-L806.
   PubMed Web of Science ®Google Scholar
• DUMITRASCU R, WEISSMANN N, GHOFRANI HA et al.: Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation (2006) 113:286-295.
   PubMed Web of Science ®Google Scholar
• DERUELLE P, BALASUBRAMANIAM V, KUNIG AM, SEEDORF GJ, MARKHAM NE, ABMAN SH: BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol. Neonate (2006) 90:135-144.
   PubMedGoogle Scholar
• ZHAO L, BROWN LA, OWJI AA et al.: Adrenomedullin activity in chronically hypoxic rat lungs. Am. J. Physiol. (1996) 271:H622-H629.
   PubMed Web of Science ®Google Scholar
• MCLATCHIE LM, FRASER NJ, MAIN MJ et al.: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature (1998) 393:333-339.
   PubMed Web of Science ®Google Scholar
• KATO J, TSURUDA T, KITA T, KITAMURA K, ETO T: Adrenomedullin: a protective factor for blood vessels. Arterioscler. Thromb. Vasc. Biol. (2005) 25:2480-2487.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, NISHIKIMI T, UEMATSU M et al.: Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart (2000) 84:653-658.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, KYOTANI S, UEMATSU M et al.: Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation (2004) 109:351-356.
   PubMed Web of Science ®Google Scholar
• GUNAYDIN S, IMAI Y, TAKANASHI Y et al.: The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine. Cardiovasc. Surg. (2002) 10:138-145.
   PubMedGoogle Scholar
• SODERMAN C, ERIKSSON LS, JUHLIN-DANNFELT A, LUNDBERG JM, BROMAN L, HOLMGREN A: Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects. Clin. Physiol. (1993) 13:677-685.
   PubMedGoogle Scholar
• ISHIHARA T, SHIGEMOTO R, MORI K, TAKAHASHI K, NAGATA S: Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron (1992) 8:811-819.
   PubMed Web of Science ®Google Scholar
• USDIN TB, BONNER TI, MEZEY E: Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology (1994) 135:2662-2680.
   PubMed Web of Science ®Google Scholar
• BUSTO R, CARRERO I, BODEGA G, ZAPATERO J, PRIETO JC: Immunohistochemical and immunochemical evidence for expression of human lung PACAP/VIP receptors. Ann. NY Acad. Sci. (2000) 921:308-311.
   PubMed Web of Science ®Google Scholar
• PETKOV V, MOSGOELLER W, ZIESCHE R et al.: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. (2003) 111:1339-1346.
   PubMed Web of Science ®Google Scholar
• ARORA A, SCHOLAR EM: Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. (2005) 315:971-979.
   PubMed Web of Science ®Google Scholar
• SCHERMULY RT, DONY E, GHOFRANI HA et al.: Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. (2005) 115:2811-2821.
   PubMed Web of Science ®Google Scholar
• BERMAN E, NICOLAIDES M, MAKI RG et al.: Altered bone and mineral metabolism in patients receiving imatinib mesylate. N. Engl. J. Med. (2006) 354:2006-2013.
   PubMed Web of Science ®Google Scholar
• KERKELA R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12:908-916.
   PubMed Web of Science ®Google Scholar
• MERKLINGER SL, JONES PL, MARTINEZ EC, RABINOVITCH M: Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation (2005) 112:423-431.
   PubMed Web of Science ®Google Scholar
• CHEN Z, LEE FY, BHALLA KN, WU J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol. Pharmacol. (2006) 69:1527-1533.
   PubMed Web of Science ®Google Scholar
• BERGERS G, SONG S, MEYER-MORSE N, BERGSLAND E, HANAHAN D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. (2003) 111:1287-1295.
   PubMed Web of Science ®Google Scholar
• BARONI SS, SANTILLO M, BEVILACQUA F et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. (2006) 354:2667-2676.
   PubMed Web of Science ®Google Scholar
• MASON JC: Statins and their role in vascular protection. Clin. Sci. (2003) 105:251-266.
   PubMed Web of Science ®Google Scholar
• LIAO JK: Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. (2002) 110:285-288.
   PubMed Web of Science ®Google Scholar
• EMMANUELE L, ORTMANN J, DOERFLINGER T, TRAUPE T, BARTON M: Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem. Biophys. Res. Commun. (2003) 302:67-72.
   PubMed Web of Science ®Google Scholar
• HATTORI Y, NAKANISHI N, AKIMOTO K, YOSHIDA M, KASAI K: HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. (2003) 23:176-182.
   PubMed Web of Science ®Google Scholar
• GIRGIS RE, LI D, ZHAN X et al.: Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Heart Circ. Physiol. (2003) 285:H938-H945.
   PubMedGoogle Scholar
• NISHIMURA T, FAUL JL, BERRY GJ et al.: Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. (2002) 166:1403-1408.
   PubMed Web of Science ®Google Scholar
• NISHIMURA T, VASZAR LT, FAUL JL et al.: Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation (2003) 108:1640-1645.
   PubMed Web of Science ®Google Scholar
• KAO PN: Simvastatin treatment of pulmonary hypertension: an observational case series. Chest (2005) 127:1446-1452.
   PubMed Web of Science ®Google Scholar
• BUDZYN K, MARLEY PD, SOBEY CG: Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol. Sci. (2006) 27:97-104.
   PubMed Web of Science ®Google Scholar
• LOIRAND G, GUERIN P, PACAUD P: Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. (2006) 98:322-334.
   PubMed Web of Science ®Google Scholar
• ABE K, SHIMOKAWA H, MORIKAWA K et al.: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. (2004) 94:385-393.
   PubMed Web of Science ®Google Scholar
• FAGAN KA, OKA M, BAUER NR et al.: Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 287:L656-L664.
   PubMed Web of Science ®Google Scholar
• NAGAOKA T, FAGAN KA, GEBB SA et al.: Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 171:494-499.
   PubMed Web of Science ®Google Scholar
• GUILLUY C, SAUZEAU V, ROLLI-DERKINDEREN M et al.: Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br. J. Pharmacol. (2005) 146:1010-1018.
   PubMed Web of Science ®Google Scholar
• ABE K, MORIKAWA K, HIZUME T et al.: Prostacyclin does not inhibit rho-kinase: an implication for the treatment of pulmonary hypertension. J. Cardiovasc. Pharmacol. (2005) 45:120-124.
   PubMed Web of Science ®Google Scholar
• FUKUMOTO Y, MATOBA T, ITO A et al.: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart (2005) 91:391-392.
   PubMed Web of Science ®Google Scholar
• HONG Z, SMITH AJ, ARCHER SL et al.: Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation (2005) 112:1494-1499.
   PubMed Web of Science ®Google Scholar
• PLATOSHYN O, GOLOVINA VA, BAILEY CL et al.: Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am. J. Physiol. Cell Physiol. (2000) 279:C1540-C1549.
   PubMed Web of Science ®Google Scholar
• WEIR EK, REEVE HL, HUANG JM et al.: Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation (1996) 94:2216-2220.
   PubMed Web of Science ®Google Scholar
• COGOLLUDO A, MORENO L, LODI F et al.: Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and Kv1.5 channel internalization. Circ. Res. (2006) 98:931-938.
   PubMed Web of Science ®Google Scholar
• SHIMODA LA, SYLVESTER JT, BOOTH GM et al.: Inhibition of voltage-gated K+ currents by endothelin-1 in human pulmonary arterial myocytes. Am. J. Physiol. Lung Cell Mol. Physiol. (2001) 281:L1115-L1122.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI A, LI Y, TANG B et al.: Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ. Res. (2006) 98:1072-1080.
   PubMed Web of Science ®Google Scholar
• YOUNG KA, IVESTER C, WEST J, CARR M, RODMAN DM: BMP signaling controls PASMC Kv channel expression in vitro and in vivo. Am. J. Physiol. Lung Cell Mol. Physiol. (2006) 290:L841-L848.
   PubMed Web of Science ®Google Scholar
• MICHELAKIS ED, REBEYKA I, WU X et al.: O2 sensing in the human ductus arteriosus: regulation of voltage-gated K+ channels in smooth muscle cells by a mitochondrial redox sensor. Circ. Res. (2002) 91:478-486.
   PubMed Web of Science ®Google Scholar
• YUAN XJ, WANG J, JUHASZOVA M, GAINE SP, RUBIN LJ: Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet (1998) 351:726-727.
   PubMed Web of Science ®Google Scholar
• REMILLARD CV, YUAN JX: Activation of K+ channels: an essential pathway in programmed cell death. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 286:L49-L67.
   PubMed Web of Science ®Google Scholar
• MICHELAKIS ED, MCMURTRY MS, WU XC et al.: Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation (2002) 105:244-250.
   PubMed Web of Science ®Google Scholar
• MCMURTRY MS, BONNET S, WU X et al.: Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. (2004) 95:830-840.
   PubMed Web of Science ®Google Scholar
• STACPOOLE PW, NAGARAJA NV, HUTSON AD: Efficacy of dichloroacetate as a lactate-lowering drug. J. Clin. Pharmacol. (2003) 43:683-691.
   PubMed Web of Science ®Google Scholar
• KAUFMANN P, ENGELSTAD K, WEI Y et al.: Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology (2006) 66:324-330.
   PubMed Web of Science ®Google Scholar
• YU Y, FANTOZZI I, REMILLARD CV et al.: Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc. Natl. Acad. Sci. USA (2004) 101:13861-13866.
   PubMed Web of Science ®Google Scholar
• WEISSMANN N, DIETRICH A, FUCHS B et al.: Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc. Natl. Acad. Sci. USA (2006) 103:19093-19098.
   PubMed Web of Science ®Google Scholar
• MACLEAN MR, HERVE P, EDDAHIBI S, ADNOT S: 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol. (2000) 131:161-168.
   PubMed Web of Science ®Google Scholar
• FANBURG BL, LEE SL: A new role for an old molecule: serotonin as a mitogen. Am. J. Physiol. (1997) 272:L795-L806.
   PubMed Web of Science ®Google Scholar
• MACLEAN MR, DEUCHAR GA, HICKS MN et al.: Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation (2004) 109:2150-2155.
   PubMed Web of Science ®Google Scholar
• EDDAHIBI S, HUMBERT M, FADEL E et al.: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. (2001) 108:1141-1150.
   PubMed Web of Science ®Google Scholar
• GUIGNABERT C, IZIKKI M, TU LI et al.: Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ. Res. (2006) 98(10):1323-1330.
   PubMed Web of Science ®Google Scholar
• EDDAHIBI S, HANOUN N, LANFUMEY L et al.: Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. (2000) 105:1555-1562.
   PubMed Web of Science ®Google Scholar
• GUIGNABERT C, RAFFESTIN B, BENFERHAT R et al.: Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation (2005) 111:2812-2819.
   PubMed Web of Science ®Google Scholar
• MARCOS E, ADNOT S, PHAM MH et al.: Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2003) 168:487-493.
   PubMed Web of Science ®Google Scholar
• CHAMBERS CD, HERNANDEZ-DIAZ S, VAN MARTER LJ et al.: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. (2006) 354:579-587.
   PubMed Web of Science ®Google Scholar
• KAWUT SM, HORN EM, BEREKASHVILI KK et al.: Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm. Pharmacol. Ther. (2006) 19:370-374.
   PubMed Web of Science ®Google Scholar
• HIRONAKA E, HONGO M, SAKAI A et al.: Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc. Res. (2003) 60:692-699.
   PubMed Web of Science ®Google Scholar
• KEEGAN A, MORECROFT I, SMILLIE D, HICKS MN, MACLEAN MR: Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ. Res. (2001) 89:1231-1239.
   PubMed Web of Science ®Google Scholar
• LAUNAY JM, HERVE P, PEOC’H K et al.: Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. (2002) 8:1129-1135.
   PubMed Web of Science ®Google Scholar
• MIYATA M, ITO M, SASAJIMA T, OHIRA H, SATO Y, KASUKAWA R: Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. Lung (2000) 178:63-73.
   PubMed Web of Science ®Google Scholar
• MORECROFT I, HEELEY RP, PRENTICE HM, KIRK A, MACLEAN MR: 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br. J. Pharmacol. (1999) 128:730-734.
   PubMed Web of Science ®Google Scholar
• COGOLLUDO A, MORENO L, LODI F et al.: Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and Kv1.5 channel internalization. Circ. Res. (2006) 98:931-938.
   PubMed Web of Science ®Google Scholar
• PETIT RD, WARBURTON RR, OU LC, BRINCK-JOHNSON T, HILL NS: Exogenous erythropoietin fails to augment hypoxic pulmonary hypertension in rats. Respir. Physiol. (1993) 91:271-282.
   PubMedGoogle Scholar
• PETIT RD, WARBURTON RR, OU LC, HILL NS: Pulmonary vascular adaptations to augmented polycythemia during chronic hypoxia. J. Appl. Physiol. (1995) 79:229-235.
   PubMed Web of Science ®Google Scholar
• WEISSMANN N, MANZ D, BUCHSPIES D et al.: Congenital erythropoietin over-expression causes ‘anti-pulmonary hypertensive’ structural and functional changes in mice, both in normoxia and hypoxia. Thromb. Haemost. (2005) 94:630-638.
   PubMed Web of Science ®Google Scholar
• SATOH K, KAGAYA Y, NAKANO M et al.: Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation (2006) 113:1442-1450.
   PubMed Web of Science ®Google Scholar
• URAO N, OKIGAKI M, YAMADA H et al.: Erythropoietin-mobilized endothelial progenitors enhances reendothelialization via Akt-endothelial nitric oxide synthase activation and prevents neointimal hyperplasia. Circ. Res. (2006) 98(11):1405-1413.
   PubMed Web of Science ®Google Scholar
• COWAN KN, JONES PL, RABINOVITCH M: Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J. Clin. Invest. (2000) 105:21-34.
   PubMed Web of Science ®Google Scholar
• JONES PL, COWAN KN, RABINOVITCH M: Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am. J. Pathol. (1997) 150:1349-1360.
   PubMed Web of Science ®Google Scholar
• ZAIDI SH, YOU XM, CIURA S, HUSAIN M, RABINOVITCH M: Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation (2002) 105:516-521.
   PubMed Web of Science ®Google Scholar
• YOUNG KA, IVESTER C, WEST J, CARR M, RODMAN DM: BMP signaling controls PASMC Kv channel expression in vitro and in vivo. Am. J. Physiol. Lung Cell Mol. Physiol. (2006) 290:L841-L848.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, GOTO N, KOJIMA Y et al.: Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. (2006) 290:L450-L458.
   PubMed Web of Science ®Google Scholar
• WU X, CHANG MS, MITSIALIS SA, KOUREMBANAS S: Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1. Circ. Res. (2006) 99:240-247.
   PubMed Web of Science ®Google Scholar
• IHIDA K, MCKEAN DM, LANE K et al.: BMP type II receptor mutations linked to familial forms of primary pulmonary hypertension regulate tenascin-C via induction of Prx1. Mol. Biol. Cell (2004) 15:7A-8A.
   Google Scholar
• HU H, SUNG A, ZHAO G et al.: Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem. Biophys. Res. Commun. (2006) 339:59-64.
   PubMed Web of Science ®Google Scholar
• YANG X, LONG L, SOUTHWOOD M et al.: Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ. Res. (2005) 96:1053-1063.
   PubMed Web of Science ®Google Scholar
• ZHANG S, FANTOZZI I, TIGNO DD et al.: Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. (2003) 285:L740-L754.
   PubMed Web of Science ®Google Scholar
• MORRELL NW, YANG X, UPTON PD et al.: Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins. Circulation (2001) 104:790-795.
   PubMed Web of Science ®Google Scholar
• STURROCK A, CAHILL B, NORMAN K et al.: Transforming growth factor-β1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. (2006) 290:L661-L673.
   PubMed Web of Science ®Google Scholar
• BRINDLE NP, SAHARINEN P, ALITALO K: Signaling and functions of angiopoietin-1 in vascular protection. Circ. Res. (2006) 98:1014-1023.
   PubMed Web of Science ®Google Scholar
• OGAWA A, NAKAMURA K, MATSUBARA H et al.: Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation (2005) 112:1806-1812.
   PubMed Web of Science ®Google Scholar
• GUI Y, ZHENG XL: 2-Methoxyestradiol induces cell cycle arrest and mitotic cell apoptosis in human vascular smooth muscle cells. Hypertension (2006) 47:271-280.
   PubMed Web of Science ®Google Scholar
• TOFOVIC SP, SALAH EM, MADY HH, JACKSON EK, MELHEM MF: Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J. Cardiovasc. Pharmacol. (2005) 46:430-437.
   PubMed Web of Science ®Google Scholar
• SMITH AM, JONES RD, CHANNER KS: The influence of sex hormones on pulmonary vascular reactivity: possible vasodilator therapies for the treatment of pulmonary hypertension. Curr. Vasc. Pharmacol. (2006) 4:9-15.
   PubMedGoogle Scholar
• CAMPBELL AI, KULISZEWSKI MA, STEWART DJ: Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. (1999) 21:567-575.
   PubMed Web of Science ®Google Scholar
• CAMPBELL AI, ZHAO Y, SANDHU R, STEWART DJ: Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation (2001) 104:2242-2248.
   PubMed Web of Science ®Google Scholar
• ZHAO YD, CAMPBELL AI, ROBB M, NG D, STEWART DJ: Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ. Res. (2003) 92:984-991.
   PubMed Web of Science ®Google Scholar
• ZHAO YD, COURTMAN DW, DENG Y, KUGATHASAN L, ZHANG Q, STEWART DJ: Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ. Res. (2005) 96:442-450.
   PubMed Web of Science ®Google Scholar
• ONO M, SAWA Y, FUKUSHIMA N et al.: Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats. Eur. J. Cardiothorac. Surg. (2004) 26:1092-1097.
   PubMed Web of Science ®Google Scholar
• TAHARA N, KAI H, NIIYAMA H et al.: Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum. Gene Ther. (2004) 15:1270-1278.
   PubMed Web of Science ®Google Scholar
• MCMURTRY MS, ARCHER SL, ALTIERI DC et al.: Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. (2005) 115:1479-1491.
   PubMed Web of Science ®Google Scholar
• BLANC-BRUDE OP, YU J, SIMOSA H, CONTE MS, SESSA WC, ALTIERI DC: Inhibitor of apoptosis protein survivin regulates vascular injury. Nat. Med. (2002) 8:987-994.
   PubMed Web of Science ®Google Scholar
• WANG GJ, SUI XX, SIMOSA HF, JAIN MK, ALTIERI DC, CONTE MS: Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler. Thromb. Vasc. Biol. (2005) 25:2081-2087.
   PubMed Web of Science ®Google Scholar
• LIEW A, BARRY F, O’BRIEN T: Endothelial progenitor cells: diagnostic and therapeutic considerations. Bioessays (2006) 28:261-270.
   PubMed Web of Science ®Google Scholar
• WERNER N, PRILLER J, LAUFS U et al.: Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1567-1572.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, MUROHARA T, SULLIVAN A et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 275:964-967.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, KALKA C, MASUDA H et al.: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. (1999) 5:434-438.
   PubMed Web of Science ®Google Scholar
• FADINI GP, SCHIAVON M, CANTINI M et al.: Circulating progenitor cells are reduced in patients with severe lung disease. Stem Cells (2006) 24(7):1806-1813.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, NAKAMURA T, TOBA T, KAJIWARA N, KATO H, SHIMIZU Y: Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng. (2004) 10:771-779.
   PubMedGoogle Scholar
• NAGAYA N, KANGAWA K, KANDA M et al.: Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation (2003) 108:889-895.
   PubMed Web of Science ®Google Scholar
• FRID MG, BRUNETTI JA, BURKE DL et al.: Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am. J. Pathol. (2006) 168:659-669.
   PubMed Web of Science ®Google Scholar
• HAYASHIDA K, FUJITA J, MIYAKE Y et al.: Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension. Chest (2005) 127:1793-1798.
   PubMed Web of Science ®Google Scholar
• PEINADO VI, RAMIREZ J, ROCA J, RODRIGUEZ-ROISIN R, BARBERA JA: Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. (2006) 34:257-263.
   PubMed Web of Science ®Google Scholar
• TEICHERT-KULISZEWSKA K, KUTRYK MJ, KULISZEWSKI MA et al.: Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ. Res. (2006) 98:209-217.
   PubMed Web of Science ®Google Scholar
• MICHELAKIS ED: Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications. Circ. Res. (2006) 98:172-175.
   PubMed Web of Science ®Google Scholar
• MACHADO RD, KOEHLER R, GLISSMEYER E et al.: Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2006) 173:793-797.
   PubMed Web of Science ®Google Scholar
• WILLERS ED, NEWMAN JH, LOYD JE et al.: Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2006) 173:798-802.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WT, RAYNOLDS MV, BADESCH DB et al.: Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J. Renin Angiotensin Aldosterone Syst. (2003) 4:27-30.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, TACACS A, STELLMACHER U, LICHTINGHAGEN R: Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension. Heart (2003) 89:445-446.
   PubMed Web of Science ®Google Scholar